Big pharma’s in-house manufacturing impacted by COVID-19 outbreak in China
According to an outlet, the in-house manufacturing of biopharma products has been threatened by the COVID-19 outbreak, especially in China.
List view / Grid view
According to an outlet, the in-house manufacturing of biopharma products has been threatened by the COVID-19 outbreak, especially in China.
The FDA has expanded the approved use of Lynparza to include the treatment of patients with metastatic breast cancer who have a BRCA gene mutation...
The FDA has granted accelerated approval to Calquence for the treatment of adults with mantle cell lymphoma...